Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas

	Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas
	Lin, Yi 2,3; Jiang, Tao 1,2; Zhou, Kaijia 2; Xu, Li 2; Chen, Baoshi 2; Li, Guilin 2; Qiu, Xiaoguang 2; Jiang, Tianzi; Zhang, Wei4 ; Song, Sonya W.1
发表期刊	NEURO-ONCOLOGY
	2009-10-01
卷号	11 期号:5 页码:468-476
文章类型	Article
摘要	Insulin-like growth factor binding protein 2 (IGFBP-2) is a malignancy-associated protein measurable in tumors and blood. Increased IGFBP-2 is associated with shortened survival of advanced glioma patients. Thus, we examined plasma IGFBP-2 levels in glioma patients and healthy controls to evaluate its value as a plasma biomarker for glioma. Plasma IGFBP-2 levels in 196 patients with newly diagnosed glioma and 55 healthy controls were analyzed using an IGFBP-2 ELISA kit. Blood was collected before surgery, after two-cycle adjuvant chemotherapy, and at recurrence. Plasma IGFBP-2 levels were correlated with disease-free survival DFS) using Cox regression analyses. We found that preoperative plasma IGFBP-2 levels were significantly higher in high-grade glioma patients n = 43 for grade III glioma; n = 72 for glioblastoma multiforme [GBM]) than in healthy controls n = 55; p < 0.001) and low-grade (grade II) glioma patients n 5 81; p, 0.001). No significant differences in preoperative plasma IGFBP-2 levels were observed between grade III glioma and GBM patients or between grade II glioma patients and healthy controls. After recurrence, plasma IGFBP-2 levels were significantly increased in GBM patients (n = 26; p < 0.001). Preoperative plasma IGFBP-2 levels were significantly correlated with DFS in GBM patients ( hazard ratio, 1.404; 95% confidence interval, 1.078-1.828; p = 0.012). We conclude that preoperative plasma IGFBP-2 levels are significantly higher in high-grade glioma patients than in low-grade glioma patients and healthy subjects, and are significantly correlated with recurrence and DFS in patients with GBM. Longitudinal studies with a larger study population are needed to confirm these findings. Neuro-Oncology 11, 468-476, 2009 (Posted to Neuro-Oncology [serial online], Doc. D08-00199, January 22, 2009. URL http://neuro-oncology. dukejournals. org; DOI: 10.1215/15228517-2008-114)
关键词	Glioma Igfbp-2 Plasma Surrogate Biomarker Prognosis Recurrence
WOS标题词	Science & Technology ; Life Sciences & Biomedicine
关键词[WOS]	FACTOR-BINDING PROTEIN-2 ; POTENTIAL SERUM MARKER ; GROWTH-FACTOR-I ; PROSTATE-CANCER ; GLIOBLASTOMA-MULTIFORME ; MOLECULAR SUBTYPES ; OVARIAN-CANCER ; EXPRESSION ; PROGRESSION ; INSULIN-LIKE-GROWTH-FACTOR-BINDING-PROTEIN-2
收录类别	SCI
语种	英语
WOS研究方向	Oncology ; Neurosciences & Neurology
WOS类目	Oncology ; Clinical Neurology
WOS记录号	WOS:000270494800002
引用统计	被引频次：76[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	http://ir.ia.ac.cn/handle/173211/3130
专题	脑图谱与类脑智能实验室_脑网络组研究
作者单位	1.Chinese Acad Sci, LIAMA Ctr Computat Med, Natl Lab Pattern Recognit, Inst Automat, Beijing, Peoples R China 2.Capital Med Univ, Tiantan Hosp, Dept Neurosurg, Beijing, Peoples R China 3.China Med Univ, Dept Neurosurg, Affiliated Hosp 1, Shenyang, Peoples R China 4.Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
推荐引用方式 GB/T 7714	Lin, Yi,Jiang, Tao,Zhou, Kaijia,et al. Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas[J]. NEURO-ONCOLOGY,2009,11(5):468-476.
APA	Lin, Yi.,Jiang, Tao.,Zhou, Kaijia.,Xu, Li.,Chen, Baoshi.,...&Song, Sonya W..(2009).Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas.NEURO-ONCOLOGY,11(5),468-476.
MLA	Lin, Yi,et al."Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas".NEURO-ONCOLOGY 11.5(2009):468-476.